XLO (Xilio Therapeutics) EBIT per Share : $-1.74 (TTM As of Sep. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Xilio Therapeutics EBIT per Share?

Xilio Therapeutics's EBIT per Share for the three months ended in Sep. 2024 was $-0.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $-1.74.

During the past 3 years, the average EBIT per Share Growth Rate was -12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Xilio Therapeutics's EBIT per Share or its related term are showing as below:

XLO' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -65.8 Med: -38.9 Max: -12
Current: -12

During the past 5 years, the highest 3-Year average EBIT per Share Growth Rate of Xilio Therapeutics was -12.00% per year. The lowest was -65.80% per year. And the median was -38.90% per year.

XLO's 3-Year EBIT Growth Rate is ranked worse than
68.24% of 1250 companies
in the Biotechnology industry
Industry Median: 2.8 vs XLO: -12.00

Xilio Therapeutics's EBIT for the three months ended in Sep. 2024 was $-14.80 Mil.

Xilio Therapeutics EBIT per Share Historical Data

The historical data trend for Xilio Therapeutics's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xilio Therapeutics EBIT per Share Chart

Xilio Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

-0.71

-2.05

-13.39

-3.26

-2.88

Xilio Therapeutics Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
EBIT per Share	Get a 7-Day Free Trial														-0.63	-0.66	-0.59	-0.25	-0.23

Xilio Therapeutics EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Xilio Therapeutics's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-79.133	/	27.496
=	-2.88

Xilio Therapeutics's EBIT per Share for the quarter that ended in Sep. 2024 is calculated as

	EBIT per Share		(Q: Sep. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-14.803	/	63.465
=	-0.23

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.74

Xilio Therapeutics (NAS:XLO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Xilio Therapeutics EBIT per Share Related Terms

Thank you for viewing the detailed overview of Xilio Therapeutics's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Xilio Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xilio Therapeutics Inc (NAS:XLO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

828 Winter Street, Suite 300, Waltham, MA, USA, 02451

Website

https://www.xiliotx.com

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

Executives

Atlas Venture Fund Xi, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Katarina Luptakova	officer: Chief Medical Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Christopher James Frankenfield	officer: Chief Operating Officer	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Kevin M. Brennan	officer: SVP, FINANCE AND ACCOUNTING	C/O XILIO THERAPEUTICS, INC., 828 WINTER STREET, WALTHAM MA 02451
Edward C English	officer: Principal Accounting Officer	828 WINTER STREET, WALTHAM MA 02451
Tomas J. Heyman	director	C/O AKERO THERAPEUTICS, INC., 170 HARBOR WAY 3RD FLOOR, SOUTH SAN FRANCISCO CA 94080
Robert W. Ross	director	C/O SURFACE ONCOLOGY, 50 HAMPSHIRE ST., 8TH FLOOR, CAMBRIDGE MA 02139
Yuan Xu	director	C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO CA 94080
Bain Capital Life Sciences Fund Ii, L.p.	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Atlas Venture Opportunity Fund I, L.p.	10 percent owner	400 TECHNOLOGY SQUARE, 10TH FLOOR, CAMBRIDGE MA 02139
Sv7 Impact Medicine Fund Lp	10 percent owner	71 KINGSWAY, LONDON X0 WC2B 6ST
Bcls Ii Investo (gp), Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bcls Ii Investco, Lp	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Life Sciences Investors Ii, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Rivervest Venture Fund Iv, L.p.	10 percent owner	101 SOUTH HANLEY ROAD, SUITE 1850, ST. LOUIS MO 63105